
Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 in PKP2 Arrhythmogenic Cardiomyopathy November 16, 2026 Exhibit 99.2 1

Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, and the timing and likelihood of potential regulatory developments, trial design changes and approval. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs, including the outcome of ongoing discussions with the FDA regarding the design of the pivotal study to support an application for accelerated approval of LX2020, statistical analysis plan and confirmatory evidence strategy; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Forward-looking statements

CLINICAL EFFICACY 80% mean reduction in NSVT and 44% mean reduction in PVC burden at latest assessment in participants in high-dose cohorts (n=7) Deepening reduction in mean NSVT burden over time in high-dose cohorts 5 of 7 participants in high-dose cohorts reported symptom improvement on PGIC scale at latest visit Preliminary evidence of stabilization or improvement in cardiac function on cardiac MRI in majority of participants in high-dose cohorts SAFETY REGULATORY PATH LX2020 generally well tolerated across 10 participants dosed No clinically significant complement activation and no study discontinuations FDA open to guideline-defined NSVT1,2 as a primary surrogate endpoint to support potential accelerated approval of LX2020 Finalization of pivotal study design, statistical analysis plan and confirmatory evidence strategy expected in 1H 2027 Lexeo expects to initiate pivotal study under accelerated approval pathway in 2H 2027 Interim LX2020 data demonstrate clinically meaningful reductions in severe arrhythmia burden 1 2 3 NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular contractions; PGIC, Patient Global Impression of Change. Sources: (1) Al-Khatib SM, et al. Circulation. 2018;138:e272–e391. (2) Carrick RT, et al. Circ Arrhythm Electrophysiol. 2022;15:e011207. NSVT defined in guidelines as hemodynamically stable ventricular tachycardia at a rate of >100 beats per minute, lasting three or more beats and less than 30 seconds.

Significant commercial potential for LX2020 given unmet need and global patient population 60K Patients in the U.S. >$4-6B Total addressable market opportunity Larger-rare, diagnosed population Significant commercial upside at peak Trial ready Broad patient pool expected to support rapid recruitment Manufacturing scale Differentiated Lexeo process will enable rapid and cost-efficient supply Global prevalence Pivotal study feasible across US, EU, Asia and other geographies

Treatment response in PKP2-ACM may be reflected across complementary measures of disease activity ACM, arrhythmogenic cardiomyopathy; PVC, premature ventricular contraction; NSVT, non-sustained ventricular tachycardia; VA, ventricular arrhythmia; ICD, implantable cardioverter defibrillator; RVEF, right ventricular ejection fraction; AAD, anti-arrhythmia drug. Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (2) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385; (3) Elias Neto J, et al. Arq Bras Cardiol. 2019;112(1):91-103; (4) Wang W, et al. Europace. 2019;21(1):9-21. Measurements of arrhythmia and function have been assessed within individuals and across ACM populations Patient-reported outcomes Treatment escalation (changes in AADs, ablation, transplant) Patient & clinical burden Despite currently available treatment options, patients continue to experience significant negative impact on quality of life PVC burden NSVT burden Sustained VA / ICD shocks Arrhythmicactivity Duration, frequency and proportion of patients experiencing events are evaluable parameters Right ventricular ejection fraction (RVEF) RV size and volumes Myocardial strain / contractility Myocardial structure & function Improvements in muscle strain may precede RV functional improvements due to existing scar tissue ACM / ARVC heart

Ventricular arrhythmic activity exists along a spectrumof increasing complexity and clinical consequence Non-sustained Ventricular Tachycardia (NSVT) Three or more consecutive ventricular beats lasting < 30 seconds at a ventricular rate of > 100 bpm1 Indicates increased ventricular electrical instability and a higher risk of sustained arrhythmias, particularly in structural heart disease such as ACM SustainedVentricular Tachycardia (VT) Continuous ventricular tachycardia either lasting ≥ 30 seconds or requiring intervention to terminate Associated with significantly greater risk of hemodynamic compromise, degeneration to ventricular fibrillation, and sudden death Serious ClinicalOutcomes If sustained VT persists, an implantable cardioverter-defibrillator (ICD) can detect the arrhythmia and deliver a shock to restore a normal heart rhythm. If sustained VT degenerates into ventricular fibrillation (VF) or is not terminated, it can lead to sudden cardiac death. Increasing Arrhythmic Risk Isolated PVC NSVT Sustained VT ICD Firing / SCD Premature Ventricular Contractions (PVCs) Early ventricular beats that occur before the next expected heartbeat Common in the general population In structural heart disease (e.g., ACM), PVCs are more frequent ICD Firing Sudden Cardiac Death (SCD) Arrhythmia Burden Sustained VT(does not self-terminate) Run of NSVT(terminates spontaneously) Isolated PVC Sources: (1) Al-Khatib SM, et al. Circulation. 2018;138(13):e272-e391. NSVT defined in guidelines as hemodynamically stable ventricular tachycardia at a rate of >100 beats per minute, lasting three or more beats and less than 30 seconds.

NSVT history and incidence is high among ACM patients with ICDs Arrhythmia Burden NSVT-ASSOCIATED ICD IMPLANTATION NSVT IS AN ESTABLISHED THRESHOLD FOR ICD DECISIONS ~1.7x higher rate of ICD implantation in patients with a history of NSVT1 NSVT is a clinically relevant marker included in major ACM risk models2, with ≥1 NSVT per day as an established threshold to predict future sustained and life-threatening VA3. NSVT history is a major risk factor supporting ICD implantation4 NSVT is an established criteria for ICD intervention ~75% of ACM patients have ICDs5 Most ACM patients have ICDs ICDs remain standard of care for most ACM patients, for both primary and secondary prevention4 ICD HISTORY ENRICHES FOR AN IDENTIFIABLE POPULATION 80-100% of patients in SNAPSHOT (n=15) and HEROIC (n=10) studies respectively had NSVT burden at baseline Holter Inclusion criteria that specify ICD implantation and a minimum daily threshold of PVCs select for a trial population with clinically meaningful, measurable NSVT burden ICD eligibility criteria may select more patients with underlying NSVT NSVT, non-sustained ventricular tachycardia; ACM, arrhythmogenic cardiomyopathy; ICD, implantable cardioverter defibrillator; VA, ventricular arrhythmia; PVC, premature ventricular contraction. Sources: (1) Carrick RT, et al. Euro Heart Journal. 2024;45:538-548. (2) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (3) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385. (4) Corrado D, et al. Circulation. 2015;132(5):441-453, (5) Bosman LP, et al. Europace. 2021;00:1-10.

Ejection fraction and RV free wall strain providecomplementary views of systolic function in ACM Ejection fraction (EF) Pump output Percentageof ventricular blood volume ejected witheach contractionof the RV or LV Global measure of systolic function EF may remain stable in early ACM LVEF largely preserved in those with early-stage ACM1 RV dysfunction often precedes overt LV dysfunction during ACM progression associated with increased severe ventricular arrhythmic risk in ACM2 RV free wall strain Muscle function Percentage shortening of the RV free wall muscle during systolic contraction More sensitivemarker of function RV strain changes earlier and faster Abnormal RV Free Wall Strain MEASUREMENT PROGRESSION IN ACM OUTCOMES RV strain abnormalities emerge before RVEF shows any deterioration1 In those with early-stage ACM, RV free wall strain worsened by ~0.6% points per year on average represents more advanced stage of ACM, associated with increased risk of cardiac death and transplantation3,4 Increased structural progression risk5 with abnormal strain > -20% Increased VA risk6with abnormalstrain > −17% Lower RVEF Lower LVEF LVEF (%) Follow up (years) Age 30-50 years 40 50 60 0 5 10 15 P = 0.835 RVfwLS (%) Follow up (years) Age 30-50 years -20 -15 -10 0 5 10 15 P < 0.001 -25 VA-free survival Time (years) 1.00 0.75 0.50 0.25 0.00 0 2 6 10 4 8 >-17 -17 to -24 <-24 Cardiac Function RV, right ventricular; ACM, arrhythmogenic cardiomyopathy; LV, left ventricular; RVEF, right ventricular ejection fraction; LVEF, left ventricular ejection fraction; VA, ventricular arrhythmia. Sources: (1) Kirkels FP, et al. J Am Coll Cardiol. 2023;82(9):785-797. (2) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (3) Corrado D, et al. Heart. 2022;108(9):733-742. (4) Luo Y, et al. ESC Heart Fail. 2023;10(5):3028-3037. (5) Malik N, et al. J Am Heart Assoc. 2020;9(7):e015016. (6) Kirkels FP, et al. Eur Heart J Cardiovasc Imaging. 2023;24(12):1710-1718.

LX2020 is being evaluated in an ongoing Phase 1/2 study:HEROIC-PKP2 2 Key Inclusion Criteria Adults (18-65 years) Diagnosis of ACM with documented PKP2 mutation Existing ICD that is MRI compatible Minimum threshold of PVCs/24-hr Neutralizing anti-AAVrh.10titer cutoff 1 Study Design & Objective Design: 52-week open-label study with a 4-year long term follow up Objective: To assess the safety and efficacy of LX2020 in individuals with PKP2-ACM High dose (n=7): 6.0x1013 vg/kg Low dose (n=3): 2.0x1013 vg/kg 52-Week Fully Enrolled 3 Key Measurements Change in symptoms (NYHA Class and PROs) Ventricular arrhythmiasand associated measures (PVC, NSVT, VT, QRS) Cardiac structure & function (EF, EDV, ESV, RV strain) Vector Transduction& Expression ACM, arrhythmogenic cardiomyopathy; ICD, implantable cardioverter defibrillator; PVC, premature ventricular contraction; NSVT, non-sustained ventricular tachycardia; VT, ventricular tachycardia; EF, ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; RV, right ventricular; NYHA, New York Heart Association; PROs, patient reported outcomes. Note: LX2020 is administered systemically; participants receive immune suppression with prednisone and sirolimus on the day prior to treatment through ~14 weeks following LX2020 dosing.

Baseline characteristics consistent with PKP2-ACM,with more severe arrhythmia burden in high-dose cohorts Cohort 1 (2.0x1013 vg/kg) Cohorts 2 & 3 (6.0x1013 vg/kg) Participant 1 2 3 4 5 6 7 84 9 10 Age, years 34 22 29 44 43 30 41 41 28 39 Age at diagnosis 27 21 28 29 28 27 30 34 16 37 Gender M M M M F F F F M M PVC per 24h1 1068 2849 2630 4780 3329 4826 4384 6308 773 5524 NSVT per 7 days1 1 3 2 31 8 13 24 1 5 8 T-wave inversion 5 0 2 3 3 3 3 3 4 0 QRS duration, ms 124 84 112 90 90 68 90 94 110 106 RVEF (%)2 43 52 42 31 34 33 42 52 43 47 NYHA class I I II I I I I I I I Follow-up, months2 24 18 123 18 18 12 12 12 12 9 Relevant medical history priorto study Sustained VT, ICD shock, ablation Sustained VT, syncope, ICD shock Sustained VT, syncope Sustained VT, VT storm, ICD shock, ablation Sustained VT, ICD shock Sustained VT, near syncope Sustained VT, syncope, ablation, stable useof flecainideat study start Sustained VT, VT storm, ICD shock, ablation Sustained VT, syncope ACM, arrhythmogenic cardiomyopathy; PVC, premature ventricular contraction; NSVT, non-sustained ventricular tachycardia; RVEF, right ventricular ejection fraction; NYHA, New York Heart Association; VT, ventricular tachycardia; ICD, implantable cardioverter defibrillator. (1) NSVT and PVC baselines updated from January 2026 using guideline-defined NSVT criteria. NSVT runs <100bpm reclassified. Minor PVC count corrections also applied. See Oct. 21, 2026 event for details. (2) Cardiac MRI conducted at 6-, 12- and 24-months of follow up but results lag Holter data. RVEF data were collected during 12-month visit, except for participant 1 at 24-months and participants 9 and 10 at 6-months. (3) Participant 3 declined 18-month follow up visit but is expected for 24-month follow up. (4) Participant 8 on flecainide at study start; no other participants taking background anti-arrhythmic drugs (AADs) at study start.

In high-dose cohorts, 80% mean improvement in NSVTand 44% mean improvement in PVCs at latest assessment Cohort Part. # Latest Visit1 (months) ∆ PVC / 24H Baseline → LV ∆ NSVT / 7d Baseline → LV ∆ RVEF %1 Baseline → LV ∆ RV Strain %1 Baseline → LV ∆ PGIC Scale Baseline LV LowDose Cohort 1 (2E13 vg/kg) #1 (M) 24 -57% 1068 → 460 -100% 1 → 0 43 40 -22 → -19 3 3 #2 (M) 18 -1% 2849 → 2807 -23% 3 → 2 52 49 -20 → -20 3 1 #3 (M)2 12 +82% 2630 → 4787 +717% 2 → 17 42 41 -20 → -22 3 4 Mean +23% +213% Majority stable 1/3 improved HighDose Cohort 2 & Cohort 3 (6E13 vg/kg) #4 (M) 18 -48% 4780 → 2472 -86% 31 → 4 31 40 -20 → -17 3 2 #5 (F) 18 +74% 3329 → 5801 -25% 8 → 6 34 33 -12 → -16 3 3 #6 (F) 12 -38% 4826 → 2998 -81% 13 → 2 33 36 -16 → -15 3 2 #7 (F)3 12 -83% 4384 → 752 -96% 24 → 1 42 37 -13 → -19 3 3 #8 (F) 12 -50% 6308 → 3171 +228% 1 → 3 52 48 -19 → -22 3 2 #9 (M) 12 +47% 773 → 1138 -76% 5 → 1 43 39 -15 → -19 3 2 #10 (M) 9 -94% 5524 → 341 -100% 8 → 0 47 43 -14 → -19 3 1 Mean -44% -80% Majority stable or improved 5/7 improved Data cutoff October 15, 2026. RVEF and RV strain values are percentages, changes reported are absolute change (percentage points). LV = latest visit. (1) Cardiac MRI conducted at 6-, 12- and 24-months of follow up but results lag Holter data. RVEF data shown were collected during 12-month visit, except for participant 1 at 24-months and participants 9 and 10 at 6-months. RV strain data shown were collected during 12-month visit except for participants 6, 9, and 10 at 6-months. (2) Participant 3 started background anti-arrhythmic therapy during the study period to manage a PVC spike. Participant declined 18-month follow up visit but is expected for 24-month follow up. (3) Participant 7 started background anti-arrhythmic therapy during the study period to manage VT approximately three months after dosing.

n=3 n=7 n=3 n=6 n=2 n=2 n=1 n=7 n=15 n=6 Deepening reduction in NSVT observed, while naturalhistory shows progressively increased arrhythmic burden Mean NSVT Change: NSVT / 7d NSVT / 7d Deepening NSVT reduction over time with 80% mean reduction at latest visit in high-dose cohorts (n=7) In contrast, participants in SNAPSHOT natural history study demonstrated 53% increase in NSVT at 12 months (n=15) Mean NSVT Change: Participant 3 (low dose) declined 18-month follow up visit but is expected for 24-month follow up.

83% of high-dose cohort had less than 1 NSVT per day at 12 months, a clinically relevant threshold for ACM management n=6 n=2 n=7 n=15 % Participants with Significant NSVT Burden(at least 7 NSVT / 7d; High-dose Cohort) ≥7 NSVT / 7d The presence of NSVT is a clinically relevant marker for risk stratification, monitoring, and management, included in major ACM risk models1 ≥1 NSVT per day is a strong predictor of future sustained and life-threatening ventricular arrhythmias2 While the majority of participants in high-dose cohorts exceeded this threshold at baseline, increasing future arrhythmic risk, 5 of 6 participants had fewer than 1 NSVT per day at 12 months In contrast, natural history demonstrated an increase in NSVT burden over one year, despite existing standard of care Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (2) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385.

100% of high-dose participants were below the clinically relevant threshold for NSVT (<1/day) at latest Holter NSVT Change: NSVT / 7d Baseline 6 Mo (n=7) 9 Mo (n=7) 12 Mo (n=6) 18 Mo (n=2) Mean change from baseline - +5% -31% -56% -59% Participants below 1 NSVT/day (<7/7d) 2/7 29% 5/7 71% 4/7 57% 5/6 83% 2/2 100% Mean change from baseline - - - +53% ≥1 NSVT per day is a strong predictor of future sustained VT risk1 All high-dose participants below the clinically relevant threshold for NSVT management at latest visit; 83% responder rate at 12 months NSVT improved in 6/7 participants at latest visit relative to baseline In most participants, NSVT reductions were substantial, greater than the relative risk reduction expected from standard of care HEROIC SNAPSHOT NSVT, non-sustained ventricular tachycardia; VT, ventricular tachycardia.Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9.

n=3 n=7 n=6 n=2 n=1 n=2 n=3 n=7 n=6 n=15 LX2020 reduced mean PVC burden by 44% in high-dose cohorts at latest assessment Mean PVC Change: Mean PVC Change: PVC / 24h PVC / 24h Mean PVC count decreased 44% at latest assessment across participants in high-dose cohorts (n=7) In contrast, participants in SNAPSHOT natural history study demonstrated a 14% decrease in PVCs at 12 months (n=15) PVC reductions were observed alongside substantial and deepening reductions in NSVT PVC burden and NSVT provide complementary measures of arrhythmic disease activity; greater variability in PVC measurements is well recognized and may reflect the influence of physical activity and other external factors1,2,3 Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9; (2) Towbin JA, et al. Heart Rhythm. 2019;16(11):e301-e372. (3) 1) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385. Participant 3 (low dose) declined 18-month follow up visit but is expected for 24-month follow up.

Evidence of improved systolic function with RV free wall strain improvements and EF stabilization n=3 n=7 n=4 n=3 Improvement Mean RV Wall Strain: RV Wall Strain % RV free wall longitudinal strain, assessed via cardiac MRI, measures the percentage shortening of the RV free wall during systole RV wall strain reflects systolic performance and regional RV muscle function; abnormal or reduced shortening reflects early RV dysfunction1 Mean RV free wall strain improved following gene therapy treatment in high-dose cohorts RVEF and LVEF preserved or improved in the majority of participants at latest visit, potentially indicative of slowed disease progression and improved function Sources: (1) Kirkels FP, et al. J Am Coll Cardiol. 2023;82(9):785-797. Cardiac MRI conducted at 6-, 12- and 24-months of follow up but results lag Holter data. RV strain data shown were collected during 12-month visit except for participants 6, 9, and 10 at 6-months.

Supportive findings from cardiac biopsy and ECG LX2020 not detected in pre-dose VCN or mRNA samples as expected. Participant 3 elected not to undergo a post-treatment biopsy. Participant 1 VCN not performed due to insufficient remaining cardiac biopsy tissue following other analyses. GAPDH normalized. Fibrofatty tissue (characteristic of ACM) may impact biopsy samples. Cardiac biopsy not expected in planned pivotal study. Lab vendor identified an error with respect to Patient 2 in PKP2 expression data, impacting the low dose mean. Previously reported data for Patient 2 was 115% and corrected value is 109%. ECG data shown were collected during latest visit except for participant 5 at 12-months, due to a site submission delay. Wagner GS, et al. J Am Coll Cardiol. 2009. Post-Dose Levels1 Post-Dose Vector Copy Number (VCN)1 Post-Dose Exogenous PKP2 (mRNA)1 PKP2 Change from Baseline (Western Blot)3 T-Wave Inversion5 QRS Duration5 Cardiac Biopsy: Dose-dependent increases in mean VCN, mRNA and western blot ECG: T-wave inversion and QRS duration stable across participants Vector copies / diploid genome Copies / µg nucleic acid ng/µg protein Leads Milliseconds (ms) Upper Limit of Normal6

Safety update: Treatment with LX2020 generally well tolerated to date LX2020 generally well tolerated across 10 participants dosed No clinically significant complement activation No study discontinuations Previously disclosed LFT elevations observed in high-dose cohorts were successfully managed per protocol with no hospitalizations or complications One previously disclosed Grade 3 SAE of sustained ventricular tachycardia (VT) was observed three months after dosing. This event is consistent with the natural course of PKP2-ACM and its known clinical manifestations. The participant was successfully treated with anti-arrhythmic medication and discharged with no additional intervention required

Summary of results and next steps for LX2020 Meaningful Clinical Activity LX2020 continues to demonstrate improvements across multiple measures of disease burden andpatient experience IncreasingConfidence in Dataset Additional follow-up strengthens the durability, consistency, and overall benefit-risk profile of LX2020 Clear PathForward Regulatory feedback supports continued advancementof LX2020 toward a potential pivotal study Interim HEROIC-PKP2 data continue to support LX2020's potentialas the first disease-modifying therapy for PKP2-ACM 1 2 3

Thank you to the ACM community Individuals and families impacted by genetically mediated cardiovascular diseases are at the center of our mission We are grateful to the participants, caregivers, investigators, advocacy organizations and broader ACM community who contributed to HEROIC-PKP2 We remain committed to advancing research, awareness, diagnosis and treatment for individuals living with PKP2-ACM

Thank you